View Item 

Show simple item record

American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection

dc.contributor.authorChey, William D.en_US
dc.contributor.authorWong, Benjamin C. Y.en_US
dc.date.accessioned2010-06-01T20:41:17Z
dc.date.available2010-06-01T20:41:17Z
dc.date.issued2007-08en_US
dc.identifier.citationChey, William D.; Wong, Benjamin C.Y. (2007). "American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection." The American Journal of Gastroenterology 102(8): 1808-1825. <http://hdl.handle.net/2027.42/73792>en_US
dc.identifier.issn0002-9270en_US
dc.identifier.issn1572-0241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73792
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17608775&dopt=citationen_US
dc.format.extent196325 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights2007 by Am. Coll. of Gastroenterologyen_US
dc.titleAmerican College of Gastroenterology Guideline on the Management of Helicobacter pylori Infectionen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDepartment of Medicine, University of Hong Kong, Hong Kongen_US
dc.identifier.pmid17608775en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73792/1/j.1572-0241.2007.01393.x.pdf
dc.identifier.doi10.1111/j.1572-0241.2007.01393.xen_US
dc.identifier.sourceThe American Journal of Gastroenterologyen_US
dc.identifier.citedreferenceEverhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin N Am 2000; 29: 559 – 78.en_US
dc.identifier.citedreferencePeterson WL, Fendrick AM, Cave DR, et al. Helicobacter pylori -related disease: Guidelines for testing and treatment. Arch Intern Med 2000; 160: 1285 – 91.en_US
dc.identifier.citedreferenceHowden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 2330 – 8.en_US
dc.identifier.citedreferencePaptheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: A systematic review. Clin Gastroenterol Hepatol 2006; 4: 130 – 42.en_US
dc.identifier.citedreferenceLeodolter A, Kulig M, Brasch H, et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori -associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15: 1949 – 58.en_US
dc.identifier.citedreferenceFord AC, Delaney BC, Forman D, et al. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: Systematic review and economic analysis. Am J Gastroenterol 2004; 99: 1833 – 55.en_US
dc.identifier.citedreferenceSharma VK, Sahai AV, Corder FA, et al. Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage. Aliment Pharmacol Ther 2001; 15: 1939 – 47.en_US
dc.identifier.citedreferenceLiu CC, Lee CL, Chan CC, et al. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer. Arch Intern Med 2003; 163: 2020 – 4.en_US
dc.identifier.citedreferenceGisbert JP, Khorrami S, Carballo F, et al. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004 ;( 2 ): CD004062.en_US
dc.identifier.citedreferenceFarinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology 2005; 128: 1579 – 605.en_US
dc.identifier.citedreferenceMontalban C, Norman F. Treatment of gastric mucosa-associated lymphoid tissue lymphoma: Helicobacter pylori eradication and beyond. Expert Rev Anticancer Ther 2006; 6: 361 – 71.en_US
dc.identifier.citedreferenceWundisch T, Thiede C, Morgner A, et al. Long-term follow-up gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2001; 23: 8018 – 24.en_US
dc.identifier.citedreferenceNakamura S, Matsumoto T, Suekane H, et al. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer 2005; 104: 532 – 40.en_US
dc.identifier.citedreferenceChen LT, Lin JT, Tai JJ, et al. Long-term results of anti- Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 2005; 97: 1345 – 53.en_US
dc.identifier.citedreferenceTalley NJ, Vakil N. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100: 2324 – 37.en_US
dc.identifier.citedreferenceMcColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339: 1869 – 74.en_US
dc.identifier.citedreferenceMcNamara D, Buckley M, Gilvarry J, et al. Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: A 5-year follow-up study. Helicobacter 2002; 7: 317 – 21.en_US
dc.identifier.citedreferenceMalfertheiner P, MÖssner J, Fischbach W, et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 615 – 25.en_US
dc.identifier.citedreferenceKamada T, Haruma K, Hata J, et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundi atrophic gastritis. Aliment Pharmacol Ther 2003; 18: 245 – 52.en_US
dc.identifier.citedreferenceBlum AL, Talley NJ, O'MorÁin C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339: 1875 – 81.en_US
dc.identifier.citedreferenceKoskenpato J, FÄrkkilÄ M, Sipponen P. Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia. Am J Gastroenterol 2001; 96: 2866 – 72.en_US
dc.identifier.citedreferenceFroehlich F, Gonvers JJ, Wietlisbach V, et al. Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. Am J Gastroenterol 2001; 96: 2329 – 36.en_US
dc.identifier.citedreferenceVeldhuyzen van Zanten S, Fedorak RN, Lambert J, et al. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. Am J Gastroenterol 2003; 98: 1963 – 9.en_US
dc.identifier.citedreferenceTalley NJ, Vakil N, Ballard ED 2nd, et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999; 341: 1106 – 11.en_US
dc.identifier.citedreferenceMoayyedi P, Deeks J, Talley NJ, et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: Resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98: 2621 – 6.en_US
dc.identifier.citedreferenceMoayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003 ;( 1 ): CD002096.en_US
dc.identifier.citedreferenceGilvarry J, Buckley MJ, Beattie S, et al. Eradication of H. pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 1997; 32: 535 – 40.en_US
dc.identifier.citedreferenceHsu PI, Lai KH, Tseng HH, et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 195 – 201.en_US
dc.identifier.citedreferenceHsu PI, Lai KH, Lo GH, et al. Risk factors for ulcer development in patients with non-ulcer dyspepsia: A prospective two year follow up study of 209 patients. Gut 2002; 51: 15 – 20.en_US
dc.identifier.citedreferencePandolfino JE, Howden CW, Kahrilas PJ. H. pylori and GERD: Is less more? Am J Gastroenterol 2004; 99: 1222 – 5.en_US
dc.identifier.citedreferenceVakil N, Talley NJ, Stolte M, et al. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2006; 24: 55 – 63.en_US
dc.identifier.citedreferenceCremonini F, Di Caro S, Delgado-Aros S, et al. Meta-analysis: The relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 18: 279 – 89.en_US
dc.identifier.citedreferenceRaghunath A, Hungin AP, Wooff D, et al. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: Systematic review. BMJ 2003; 326: 737 – 43.en_US
dc.identifier.citedreferenceRaghunath AS, Hungin APS, Wooff D, et al. Systematic review: The effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004; 20: 733 – 44.en_US
dc.identifier.citedreferenceLaine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastro-esophageal reflux disease symptoms: A post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97: 2992 – 7.en_US
dc.identifier.citedreferenceVakil N, Traxler BM, Levine D. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 2004; 99: 1437 – 41.en_US
dc.identifier.citedreferenceDe Wit NJ, de Boert WA, Geldof H, et al. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: Does Helicobacter pylori infection affect proton pump inhibitor effectiveness? Aliment Pharmacol Ther 2004; 20: 451 – 8.en_US
dc.identifier.citedreferenceFallone CA, Barkun AN, Mayrand S, et al. There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with Helicobacter pylori. Aliment Pharmacol Ther 2004; 20: 761 – 8.en_US
dc.identifier.citedreferenceChan FKL. NSAID-induced peptic ulcers and Helicobacter pylori infection. Implications for patient management. Drug Saf 2005; 28: 287 – 300.en_US
dc.identifier.citedreferenceSung JJY. Should we eradicate Helicobacter pylori in non-steroidal anti-inflammatory drug users? Aliment Pharmacol Ther 2004; 20 ( Suppl 2 ): 65 – 70.en_US
dc.identifier.citedreferenceHuang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 2002; 359: 14 – 22.en_US
dc.identifier.citedreferenceVergara M, CatalÁn M, Gisbert JP, et al. Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411 – 8.en_US
dc.identifier.citedreferenceSchaeverbeke T, Broutet N, Zerbib F, et al. Should we eradicate Helicobacter pylori before prescribing an NSAID? Results of a placebo-controlled study. Am J Gastroenterol 2005; 100: 2637 – 43.en_US
dc.identifier.citedreferencePapatheodoridis GV, Archimandritis AJ. Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. World J Gastroenterol 2005; 11: 3811 – 6.en_US
dc.identifier.citedreferenceEswaran S, Scheiman J, Howden CW, et al. Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: Results of a national survey. Aliment Pharmacol Ther 2006; 23: 655 – 68.en_US
dc.identifier.citedreferenceChan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967 – 73.en_US
dc.identifier.citedreferenceDuBois S, Kearney, D. Iron-deficiency anemia and Helicobacter pylori infection: A review of evidence. Am J Gastroenterol 2005; 100: 453 – 9.en_US
dc.identifier.citedreferenceBaggett HC, Parkinson AJ, Muth PT, et al. Endemic iron deficiency associated with Helicobacter pylori infection among school-aged children in Alaska. Pediatrics 2006; 117: e396 – 404.en_US
dc.identifier.citedreferenceCardenas VM, Mulla ZD, Ortiz M, et al. Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol 2006; 163: 127 – 34.en_US
dc.identifier.citedreferenceAnnibale B, Marignani M, Monarca B, et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Inten Med 1999; 131: 668 – 72.en_US
dc.identifier.citedreferenceChoe YH, Soon KK, Son BK, et al. Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents. Helicobacter 1999; 4: 135 – 9.en_US
dc.identifier.citedreferenceHacihanefioglu A, Edebali F, Celebi A, et al. Improvement of complete blood count in patients with iron deficiency anemia and Helicobacter pylori infection after the eradication of Helicobacter pylori. Hepatogastroenterology 2004; 51: 313 – 5.en_US
dc.identifier.citedreferenceGessner BD, Baggett HC, Muth PT, et al. A controlled, household-randomized, open-label trial of the effect that treatment of Helicobacter pylori infection has on iron-deficiency in children in rural Alaska. J Infect Dis 2006; 193: 537 – 46.en_US
dc.identifier.citedreferenceMalfertheiner P, Sipponen P, Naumann M, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: A state-of-the-art critique. Am J Gastroenterol 2005; 100: 2100 – 15.en_US
dc.identifier.citedreferenceLeung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: Results of a randomised trial on Helicobacter pylori eradication. Gut 2004; 53: 1244 – 9.en_US
dc.identifier.citedreferenceLey C, Mohar A, Guarner J, et al. Helicobacter pylori eradication and gastric preneoplastic conditions: A randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 2004; 13: 4 – 10.en_US
dc.identifier.citedreferenceMera R, Fontham ETH, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54: 1536 – 40.en_US
dc.identifier.citedreferenceWong BCY, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. JAMA 2004; 29: 187 – 94.en_US
dc.identifier.citedreferenceMidolo P, Marshall BJ. Accurate diagnosis of Helicobacter pylori. Urease tests. Gastroenterol Clin N Am 2000; 29: 871 – 8.en_US
dc.identifier.citedreferencePerna F, Ricci C, Gatta L, et al. Diagnostic accuracy of a new rapid urease test (Pronto Dry), before and after treatment of Helicobacter pylori infection. Minerva Gastroenterol Dietol 2005; 51: 247 – 54.en_US
dc.identifier.citedreferenceLaine L, Lewin D, Naritoku W, et al. Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pylori. Gastrointest Endosc 1996; 44: 523 – 6.en_US
dc.identifier.citedreferenceLee JM, Breslin NP, Fallon C, et al. Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding. Am J Gastroenterol 2000; 95: 1166 – 70.en_US
dc.identifier.citedreferenceTu TC, Lee CL, Wu CH et al. Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers. Gastrointest Endosc 1999; 49: 302 – 6.en_US
dc.identifier.citedreferenceGrino P, Pascual S, Such J, et al. Comparison of stool immunoassay with standard methods for detection of Helicobacter pylori infection in patients with upper-gastrointestinal bleeding of peptic origin. Eur J Gastroenterol Hepatol 2003; 15: 525 – 9.en_US
dc.identifier.citedreferenceLaine LA, Nathwani RA, Naritoku W. The effect of GI bleeding on Helicobacter pylori diagnostic testing: A prospective study at the time of bleeding and 1 month later. Gastrointest Endosc 2005; 62: 853 – 9.en_US
dc.identifier.citedreferenceGisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: A systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 848 – 63.en_US
dc.identifier.citedreferenceWoo JS, el-Zimaity HM, Genta RM, et al. The best gastric site for obtaining a positive rapid urease test. Helicobacter 1996; 1: 256 – 9.en_US
dc.identifier.citedreferenceChey WD, Woods M, Scheiman JM, et al. Lansoprazole and ranitidine affect the accuracy of the 14 C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol 1997; 92: 446 – 50.en_US
dc.identifier.citedreferenceLaine L, Estrada R, Trujillo M, et al. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998; 129: 547 – 50.en_US
dc.identifier.citedreferenceel-Zimaity HM. Accurate diagnosis of Helicobacter pylori with biopsy. Gastroenterol Clin N Am 2000; 29: 863 – 9.en_US
dc.identifier.citedreferenceDixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161 – 81.en_US
dc.identifier.citedreferenceCutler AF, Havstad S, Chen KM, et al. Accuracy of invasive and non-invasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995; 109: 136 – 41.en_US
dc.identifier.citedreferencevan IJzendoorn MC, Laheij RJ, de Boer WA, et al. The importance of corpus biopsies in the determination of Helicobacter pylori infection. Neth J Med 2005; 63: 141 – 5.en_US
dc.identifier.citedreferencePerez-Perez GI. Accurate diagnosis of Helicobacter pylori. Culture, including transport. Gastroenterol Clin N Am 2000; 29: 879 – 84.en_US
dc.identifier.citedreferenceMakristathis A, Hirschl AM, Lehourst P, et al. Diagnosis of Helicobacter pylori Infection. Helicobacter 2004; 9: 7 – 14.en_US
dc.identifier.citedreferenceLehours P, Ruskone-Fourmestraux A, Lavergne A, et al. Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma? Am J Gastroenterol 2003; 98: 291 – 5.en_US
dc.identifier.citedreferenceZsikla V, Hailemariam S, Baumann M, et al. Increased rate of Helicobacter pylori infection detected by PCR in biopsies with chronic gastritis. Am J Surg Pathol 2006; 30: 242 – 8.en_US
dc.identifier.citedreferenceLawson AJ, Elviss NC, Owen RJ. Real-time PCR detection and frequency of 16 S rDNA mutations associated with resistance and reduced susceptibility to tetracycline in Helicobacter pylori from England and Wales. Antimicrob Chemother 2005; 56: 282 – 6.en_US
dc.identifier.citedreferenceRimbara E, Noguchi N, Yamaguchi T, et al. Development of a highly sensitive method for detection of clarithromycin-resistant Helicobacter pylori from human feces. Current Microbiol 2005; 51: 1 – 5.en_US
dc.identifier.citedreferenceDe Francesco V, Margiotta M, Zullo M, et al. Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. Aliment Pharmacol Ther 2006; 23: 429 – 35.en_US
dc.identifier.citedreferenceHo GY, Windsor HM. Accurate diagnosis of Helicobacter pylori. Polymerase chain reaction tests. Gastroenterol Clin N Am 2000; 29: 903 – 15.en_US
dc.identifier.citedreferenceHo B, Marshall BJ. Accurate diagnosis of Helicobacter pylori. Serologic testing. Gastroenterol Clin N Am 2000; 29: 853 – 62.en_US
dc.identifier.citedreferenceLoy CT, Irwig LM, Katelaris PH, et al. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996; 91: 1138 – 44.en_US
dc.identifier.citedreferenceChey WD, Murthy U, Shaw S, et al. A comparison of three fingerstick, whole blood antibody tests for Helicobacter pylori infection: A United States, multicenter trial. Am J Gastroenterol 1999; 94: 1512 – 6.en_US
dc.identifier.citedreferenceNurgalieva ZZ, Graham DY. Pearls and pitfalls of assessing Helicobacter pylori status. Dig Liver Dis 2003; 35: 375 – 7.en_US
dc.identifier.citedreferenceHoang TT, Wheeldon TU, Bengtsson C, et al. Enzyme-liked immunosorbent assay for Helicobacter pylori needs adjustment for the population investigated. J Clin Microbiol 2004; 42: 627 – 30.en_US
dc.identifier.citedreferenceGisbert JP, Pajares JM. Review article: 13  C-urea breath test in the diagnosis of Helicobacter pylori infection—a critical review. Aliment Pharmacol Ther 2004; 20: 1001 – 17.en_US
dc.identifier.citedreferenceChey WD. Accurate diagnosis of Helicobacter pylori. 14  C-urea breath test. Gastroenterol Clin N Am 2000; 29: 895 – 902.en_US
dc.identifier.citedreferenceSteen T, Berstad K, Meling T, et al. Reproducibility of the 14 C-urea breath test repeated after 1 week. Am J Gastroenterol 1995; 90: 2103 – 5.en_US
dc.identifier.citedreferenceLeodolter A, DomÍngues-MuÑoz JE, von Arnim U, et al. Validity of a modified 13 C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol 1999; 94: 2100 – 4.en_US
dc.identifier.citedreferenceChey WD, Metz DC, Shaw S, et al. Appropriate timing of the 14 C-urea breath test to establish eradication of Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 1171 – 4.en_US
dc.identifier.citedreferencePerri F, Giampiero M, Neri M, et al. Helicobacter pylori antigen stool test and 13 C-urea breath test in patients after eradication treatments. Am J Gastroenterol 2002; 97: 2756 – 62.en_US
dc.identifier.citedreferenceGatta L, Ricci C, Tampieri A, et al. Accuracy of breath tests using low doses of 13 C-urea to diagnose Helicobacter pylori infection: A randomised controlled trial. Gut 2006; 55: 457 – 62.en_US
dc.identifier.citedreferenceChey WD, Murthy U, Toskes P, et al. The 13 C-urea blood test accurately detects active Helicobacter pylori infection: A United States, multicenter trial. Am J Gastroenterol 1999; 94: 1522 – 4.en_US
dc.identifier.citedreferenceAhmed F, Chey WD, Murthy U. Evaluation of the Ez-HBT Helicobacter blood test to establish Helicobacter pylori eradication. Aliment Pharmacol Ther 2005; 22: 875 – 80.en_US
dc.identifier.citedreferenceGraham DY, Opekun AR, Hammoud F, et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003; 98: 1005 – 9.en_US
dc.identifier.citedreferenceCutler AF, Elnaggar M, Brooks E, et al. Effect of standard and high dose ranitidine on 13 C-urea breath test results. Am J Gastroenterol 1998; 93: 1297 – 9.en_US
dc.identifier.citedreferenceSavarino V, Tracci D, Dulbecco P, et al. Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori. Am J Gastroenterol 2001; 96: 348 – 52.en_US
dc.identifier.citedreferenceGraham DY, Opekun AR, Jogi M, et al. False negative urea breath tests with H2-receptor antagonists: Interactions between Helicobacter pylori density and pH. Helicobacter 2004; 9: 17 – 27.en_US
dc.identifier.citedreferenceGatta L, Vakil N, Ricci C, et al. Effect of proton pump inhibitors and antacid therapy on 13 C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004; 99: 823 – 9.en_US
dc.identifier.citedreferenceGatta L, Ricci C, Tampieri A, et al. Accuracy of breath tests using low doses of 13 C-urea to diagnose Helicobacter pylori infection: A randomised controlled trial. Gut 2006; 55: 457 – 62.en_US
dc.identifier.citedreferenceGisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: A systematic review. Helicobacter 2004; 9: 347 – 68.en_US
dc.identifier.citedreferenceGisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: A systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 1921 – 30.en_US
dc.identifier.citedreferenceMalfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection–the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167 – 80.en_US
dc.identifier.citedreferenceViara D, Vakil N, Menegatti M, et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002; 136: 280 – 7.en_US
dc.identifier.citedreferenceOdaka T, Yamaguchi T, Koyama H, et al. Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. Am J Gastroenterol 2002; 97: 594 – 9.en_US
dc.identifier.citedreferenceVakil N, Rhew D, Soll A, et al. The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori. Am J Gastroenterol 2000; 95: 1691 – 8.en_US
dc.identifier.citedreferenceBravo LE, Realpe JL, Campo C, et al. Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection. Am J Gastroenterol 1999; 94: 2380 – 3.en_US
dc.identifier.citedreferenceManes G, Balzano A, Iaquinto G, et al. Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy. Aliment Pharmacol Ther 2001; 15: 73 – 9.en_US
dc.identifier.citedreferenceGrino P, Pascual S, Such J, et al. Comparison of stool immunoassay with standard methods for detection of Helicobacter pylori infection in patients with upper-gastrointestinal bleeding of peptic origin. Eur J Gastroenterol Hepatol 2003; 15: 525 – 9.en_US
dc.identifier.citedreferencePeitz U, Leodolter A, Kahl S, et al. Antigen stool test for assessment of Helicobacter pylori infection in patients with upper gastrointestinal bleeding. Aliment Pharmacol Ther 2003; 17: 1075 – 84.en_US
dc.identifier.citedreferencevan Leerdam ME, Van Der Ende A, ten Kate FJW, et al. Lack of accuracy of the noninvasive Helicobacter pylori stool antigen test in patients with gastroduodenal ulcer bleeding. Am J Gastroenterol 2003; 98: 798 – 801.en_US
dc.identifier.citedreferenceLin HJ, Lo WC, Perng CL, et al. Helicobacter pylori stool antigen test in patients with bleeding peptic ulcers. Helicobacter 2004; 9: 663 – 8.en_US
dc.identifier.citedreferenceGrino P, Pascual S, Such J, et al. Comparison of diagnostic methods for Helicobacter pylori infection in patients with upper gastrointestinal bleeding. Scand J Gastroenterol 2001; 36: 1254 – 8.en_US
dc.identifier.citedreferenceSchilling D, Demel A, Adamek HE, et al. A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study. Dig Liver Dis 2003; 35: 217 – 21.en_US
dc.identifier.citedreferenceGÜell M, Artigau E, Esteve V, et al. Usefulness of a delayed test for the diagnosis of Helicobacter pylori infection in bleeding peptic ulcer. Aliment Pharmacol Ther 2006; 23: 53 – 9.en_US
dc.identifier.citedreferenceTalley NJ. AGA Medical Position Statement: Evaluation of dyspepsia. Gastroenterology 2005; 129: 1753 – 5.en_US
dc.identifier.citedreferenceChey WD, Fendrick AM. Noninvasive Helicobacter pylori testing for the “test-and-treat” strategy: A decision analysis to assess the effect of past infection on test choice. Arch Intern Med 2001; 161: 2129 – 32.en_US
dc.identifier.citedreferenceLaine L, Sugg J, Suchower L, et al. Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori. Gastrointest Endosc 2000; 51: 664 – 9.en_US
dc.identifier.citedreferenceQasim A, Sebastian S, Thornton O, et al. Riabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21: 91 – 6.en_US
dc.identifier.citedreferenceKatelaris PH, Forbes GM, Talley NJ, et al. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE study. Gastroenterology 2002; 123: 1763 – 9.en_US
dc.identifier.citedreferenceGenÉ E, Calvet X, Azagra R, et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: A meta-analysis. Aliment Pharmacol Ther 2003; 17: 1137 – 43.en_US
dc.identifier.citedreferenceVakil N, Lanza F, Schwatrz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20: 99 – 107.en_US
dc.identifier.citedreferenceCardenas VM, Graham DY, el-Zimaity HM, et al. Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. Aliment Pharmacol Ther 2006; 23: 295 – 301.en_US
dc.identifier.citedreferenceBochenek WL, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: Results of two double-blind, randomized studies. Helicobacter 2003; 8: 626 – 42.en_US
dc.identifier.citedreferenceCalvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603 – 9.en_US
dc.identifier.citedreferencePaoluzi P, Iacopini F, Crispino P, et al. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: A large prospective single-center randomized study. Helicobacter 2006; 11: 562 – 8.en_US
dc.identifier.citedreferenceUlmer HJ, Beckerling A, Gatz G. Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: A broad data review. Helicobacter 2003; 8: 95 – 104.en_US
dc.identifier.citedreferenceVergara M, Vallve M, Gisbert JP, et al. Meta-analysis: Comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 18: 647 – 54.en_US
dc.identifier.citedreferenceVallve M, Vergara M, Gisbert JP, et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: A meta-analysis. Aliment Pharmacol Ther 2002; 16: 1149 – 56.en_US
dc.identifier.citedreferenceJanssen MJ, Laheij RJ, de Boer WA, et al. Meta-analysis: The influence of pre-treatment with a proton pump inhibitor on Helicobcacter pylori eradication. Aliment Pharmacol Ther 2005; 21: 341 – 5.en_US
dc.identifier.citedreferenceGraham DY, Hammoud F, el-Zimaity HM, et al. Meta-analysis: Proton pump inhibitor or H 2 -receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 17: 1229 – 36.en_US
dc.identifier.citedreferenceLaine L. Is it time for quadruple therapy to be first line? Can J Gastroenterol 2003; 17 ( Suppl B ): 33B – 5B.en_US
dc.identifier.citedreferenceGene E, Calvet X, Azagra R, et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: An updated meta-analysis. Aliment Pharmacol Ther 2003; 18: 543 – 4.en_US
dc.identifier.citedreferenceFischbach LA, van Zanten S, Dickason J. Meta-analysis: The efficacy, adverse events, and adherence related to first-line anti- Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004; 20: 1071 – 82.en_US
dc.identifier.citedreferenceGraham DY, Belson G, Abudayyeh S, et al. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis 2004; 36: 384 – 7.en_US
dc.identifier.citedreferenceLaine L, Hunt R, el-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: A prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562 – 7.en_US
dc.identifier.citedreferenceZullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719 – 26.en_US
dc.identifier.citedreferenceFrancavilla R, Lionetti E, Castellaneta SP, et al. Improved Efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: A randomized trial. Gastroenterol 2005; 129: 1414 – 9.en_US
dc.identifier.citedreferenceZullo A, Gatta L, de Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: A prospective controlled study. Aliment Pharmacol Ther 2005; 21: 1419 – 24.en_US
dc.identifier.citedreferenceScaccianoce G, Hassan C, Panarese A, et al. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol 2006; 20: 113 – 7.en_US
dc.identifier.citedreferenceDe Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144: 94 – 100.en_US
dc.identifier.citedreferenceMegraud F, Lamouliatte H. Review article: The treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1333 – 43.en_US
dc.identifier.citedreferenceMegraud F, Marshall BJ. How to treat Helicobacter pylori. First-line, second-line, and future therapies. Gastroenterol Clin N Am 2000; 29: 759 – 73.en_US
dc.identifier.citedreferenceSaad R, Chey WD. A clinician's guide to the diagnosis and treatment of H. pylori. Cleve Clin J Med 2005; 72: 109 – 26.en_US
dc.identifier.citedreferenceMeyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: The surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med 2002; 136: 13 – 24.en_US
dc.identifier.citedreferenceDuck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori -infected persons, United States. Emerg Infect Dis 2004; 10: 1088 – 94.en_US
dc.identifier.citedreferenceTankovic J, Lamarque D, Lascols C, et al. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Aliment Pharmacol Ther. 2001; 15; 707 – 13.en_US
dc.identifier.citedreferenceDucons JA, Santolaria S, Guirao R, et al. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: A prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999; 13: 775 – 80.en_US
dc.identifier.citedreferenceLee JH, Shin JH, Roe IH, et al. Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. Antimicrob Agents Chemother 2005; 49: 1600 – 3.en_US
dc.identifier.citedreferenceMcMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139: 463 – 9.en_US
dc.identifier.citedreferenceSuzuki T, Matsuo K, Sawaki A, et al. Systematic review and meta-analysis: Importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 24: 273 – 80.en_US
dc.identifier.citedreferencePadol S, Yuan Y, Thabane M, et al. The effect of CTP2C19 polymorphisms on H pylori eradication rate in dual and triple first-line PPI therapies: A meta-analysis. Am J Gastroenterol 2006; 101: 1467 – 75.en_US
dc.identifier.citedreferenceHojo M, Miwa H, Nagahara A, et al. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001; 36: 690 – 700.en_US
dc.identifier.citedreferenceDore MP, Marras L, Maragkoudakis E, et al. Salvage therapy after two or more prior Helicobacter pylori treatment failures: The super salvage regimen. Helicobacter 2003; 8: 307 – 9.en_US
dc.identifier.citedreferencePerri F, Festa V, Clemente R, et al. Randomized study of two “rescue” therapies for Helicobacter pylori -infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96: 58 – 62.en_US
dc.identifier.citedreferenceBock H, Koop H, Lehn N, et al. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: Preliminary experience. J Clin Gastroenterol 2000; 31: 222 – 5.en_US
dc.identifier.citedreferenceWong WM, Gu Q, Lam SK, et al. Randomised controlled study of rabeprazole, levofloxacin and rifabutin triple therapy versus quadruple therapy as second-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 553 – 60.en_US
dc.identifier.citedreferenceMiehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006; 24: 395 – 403.en_US
dc.identifier.citedreferenceBorody TJ, Pang G, Wettstein AR, et al. Efficacy and safety of rifabutin-containing ‘rescue-therapy’ for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 481 – 8.en_US
dc.identifier.citedreferenceApseloff G. Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin Pharmacol Ther 2003; 74: 591 – 2.en_US
dc.identifier.citedreferenceBhagat N, Read RW, Rao NA, et al. Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. Ophthalmology 2001; 108: 750 – 2.en_US
dc.identifier.citedreferenceGraham DY, Osato MS, Hoffman J, et al. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000; 14: 211 – 5.en_US
dc.identifier.citedreferenceIsakov V, Domareva I, Koudryavtseva L, et al. Furazolidone-based triple ‘rescue therapy’ vs. quadruple ‘rescue therapy’ for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002; 16: 1277 – 82.en_US
dc.identifier.citedreferenceCoelho LG, Moretzsohn LD, Vieira WL, et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: A pilot study. Aliment Pharmacol Ther 2005; 21: 783 – 7.en_US
dc.identifier.citedreferenceWong WM, Wong BCY, Lu H, et al. One-week omeprazole, furazolidone and amoxycillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther 2002; 16: 793 – 8.en_US
dc.identifier.citedreferenceAli BH. Pharmacological, therapeutic and toxicological properties of furazolidone: Some recent research. Vet Res Commun 1999; 23: 343 – 60.en_US
dc.identifier.citedreferenceSaad R, Schoenfeld P, Chey WD. Levofloxacin triple or PPI quadruple salvage therapy for persistent Helicobacter pylori infection: Results of a meta-analysis. Am J Gastroenterol 2006; 101: 488 – 96.en_US
dc.identifier.citedreferenceGisbert JP, de la Morena F. Systematic review and meta-analysis: Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35 – 44.en_US
dc.identifier.citedreferenceGisbert JP, Castro-Fernandez M, Bermejo F. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 2006; 101: 243 – 7.en_US
dc.identifier.citedreferenceGiannini EG, Bilardi C, Dulbecco P, et al. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Pharmacol Ther 2006; 23: 281 – 7.en_US
dc.identifier.citedreferenceBest L, Cooper-Lesins G, Haldane D, et al. Helicobacter pylori antibiotic resistance in Canadian populations. Gastroenterology 2004; 124 ( Suppl 2 ): A - 189.en_US
dc.identifier.citedreferenceMarzio L, Coraggio D, Capodicasa S, et al. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006; 11: 237 – 42.en_US
dc.identifier.citedreferenceMiyachi H, Miki I, Aoyama N, et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006; 11: 243 – 9.en_US
dc.identifier.citedreferenceBogaerts P, Berhin C, Nizet H, et al. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006; 11: 441 – 5.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1572-0241.2007.01393.x.pdf
Size:
191.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.